Acrivon Therapeutics (ACRV) Financials

Acrivon Therapeutics (NASDAQ: ACRV) remains a development-stage biotech with no revenue, sizable research spending, and a balance sheet that still appears well-funded for the near term. Over the last several quarters, the company has consistently posted operating losses in the high-teens to low-$20 millions per quarter, while cash and investments have declined but remain substantial. For retail investors, the key story is still clinical progress versus cash burn.

What stands out over the last four years is that Acrivon has not yet generated product revenue, so its financial profile is driven almost entirely by R&D investment, general and administrative spending, and the amount of cash it can preserve through its investment portfolio. The company’s operating losses have been fairly stable, but the cash balance has come down meaningfully from 2024 levels as it funds ongoing development.

• Strong liquidity position: As of Q1 2026, Acrivon held $34.1 million in cash and equivalents plus $63.7 million in short-term investments, for about $97.7 million in near-term liquidity.
• No debt shown on the balance sheet: The company’s reported liabilities were only $12.3 million in Q1 2026, which helps reduce financing risk.
• Large equity cushion: Total equity was $95.5 million in Q1 2026, still comfortably above total liabilities.
• Interest income helps offset losses: Investment income was $989,000 in Q1 2026 and has generally remained an important source of offset against operating burn.
• Operating cash outflow improved versus some prior quarters: Q1 2026 operating cash burn was $20.5 million, better than the $15.2 million to $22.6 million range seen across recent quarters, though still substantial.
• Quarterly losses remain consistent: Net loss was $19.0 million in Q1 2026, compared with $19.0 million in Q4 2025 and $18.2 million in Q3 2025.
• R&D spending remains high but fairly steady: Research and development expense was $15.2 million in Q1 2026, slightly above the prior quarter and still the main driver of losses.
• Share count has drifted higher over time: Weighted average basic shares rose to 38.7 million in Q1 2026 from 38.5 million in Q4 2025 and 38.4 million in Q3 2025, which can pressure per-share results.
• No revenue yet: Acrivon reported $0 in revenue in every quarter provided, so there is no commercial cushion against operating losses.
• Cash and investments have trended lower: Total current assets fell to $99.2 million in Q1 2026 from $130.4 million in Q3 2025 and $151.3 million in Q1 2025, reflecting ongoing burn and portfolio changes.

Balance sheet trend: The company entered 2025 with a very strong liquidity base, including $160.4 million in equity at Q1 2025 and $151.3 million in current assets. By Q1 2026, current assets had declined to $99.2 million and equity had fallen to $95.5 million, showing the cumulative effect of continuing losses. Still, the company is not in immediate balance-sheet distress based on the data provided.

Income statement trend: Acrivon’s quarterly operating expenses have generally stayed in a tight range, with total operating expenses between about $19.7 million and $25.1 million over the periods shown. Q1 2026 operating expenses of $19.9 million were slightly below several earlier quarters, which is a small positive. However, with no revenue, those expense levels still translate directly into losses.

Cash flow trend: Operating cash burn has been persistent, generally ranging from roughly $9.8 million to $20.5 million per quarter across the history shown. Investing cash flows have often been positive or negative depending on the timing of investment purchases and maturities, but those movements do not change the core story: the business is still consuming cash to fund development.

Bottom line: Acrivon Therapeutics looks financially stable enough for now, with a meaningful cash/investment position and no debt on the reported balance sheet. But investors should keep in mind that the company is still pre-revenue, still loss-making, and still dependent on capital preservation and future clinical success. The stock’s long-term case will likely hinge more on pipeline progress than on current financial performance.